CSIMarket
 
Eyenovia inc   (EYEN)
Other Ticker:  
 
 
Price: $1.5300 $-0.06 -3.774%
Day's High: $1.6393 Week Perf: -7.27 %
Day's Low: $ 1.53 30 Day Perf: -13.07 %
Volume (M): 742 52 Wk High: $ 5.85
Volume (M$): $ 1,135 52 Wk Avg: $2.26
Open: $1.63 52 Wk Low: $1.05



 Market Capitalization (Millions $) 63
 Shares Outstanding (Millions) 41
 Employees 7
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -27
 Cash Flow (TTM) (Millions $) -8
 Capital Exp. (TTM) (Millions $) 4

Eyenovia Inc
Eyenovia Inc. is a clinical stage biopharmaceutical company that specializes in developing and commercializing transformative ophthalmic products for patients. The company focuses on innovation and technology, encompassing micro-dosing drug delivery systems and therapeutic molecules. Eyenovia was founded in 2014 and is headquartered in New York, United States.

The company's mission is to address the unmet needs of the ophthalmic market and provide patients with better solutions for the treatment and management of eye diseases. Eyenovia's innovative technology aims to deliver precise doses of medications to the eye, improving efficacy, safety, and compliance.

Eyenovia has a pipeline of products focused on three areas- myopia, presbyopia, and mydriasis. Myopia is a common eye condition that causes nearsightedness, and the company's lead product candidate called MicroPine is specifically designed to treat it. MicroPine is a micro-dosing eye drop that delivers low-dose atropine to the eye to prevent the progression of myopia.

Presbyopia, another eye condition causing age-related farsightedness, is another area of interest for Eyenovia. The company's product candidate, MicroLine, is a micro-dosing eye drop that delivers pilocarpine HCl and can improve near vision in patients with presbyopia.

The third area of focus for Eyenovia is mydriasis, which is the dilation of the pupil that allows for a more thorough examination of the eye. The company's product candidate, MicroStat, is a micro-dosing eye drop that delivers phenylephrine and tropicamide for mydriasis.

Besides its pipeline of products, Eyenovia has a licensing agreement with Eton Pharmaceuticals for MicroTears in the United States, and the company also holds numerous patents and intellectual property related to its technology and products.

Eyenovia has garnered several awards and recognitions for its innovative solutions and product pipeline. These include the 2019 Ophthalmology Innovation Summit (OIS) Innovation Showcase Winner, the 2019 Red Herring Top 100 North America Winner, and the 2018 R&D 100 Award Winner.

Overall, Eyenovia is a company committed to using innovative technology to develop and commercialize transformative ophthalmic products that address unmet needs in the market. The company is well-positioned to make a significant impact on the ophthalmic industry and improve the quality of life for patients with eye diseases.


   Company Address: 295 Madison Avenue NEW YORK 10017 NY
   Company Phone Number: 393-6684   Stock Exchange / Ticker: NASDAQ EYEN
   EYEN is expected to report next financial results on March 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Eyenovia Inc

Eyenovia Inc Faces Challenges as Shares Plummet and Future Prospects Remain Uncertain



Eyenovia Inc, a major pharmaceutical preparations company, has witnessed a significant drop in its shares over the past month. This decline adds to the year-to-date poor performance. Additionally, the company is currently trading on the NASDAQ well below its 52-week average. These developments raise concerns about Eyenovia's future prospects and its ability to overcome these challenges. Furthermore, factors such as a co-promotion agreement and recent financial results also contribute to the uncertainty surrounding the company's future.
1. Co-Promotion Agreement with NovaBay Pharmaceuticals:
Eyenovia's strategic partnership with NovaBay Pharmaceuticals aims to expand market presence and provide a wider range of ophthalmic solutions. Under this agreement, NovaBay will market Eyenovia's Clobetasol propionate ophthalmic suspension, while Eyenovia will promote NovaBay's Avenova Antimicrobial Lid & Lash Solution. This collaboration intends to effectively target eye care professionals across the United States. However, the impact and success of this agreement remain to be seen.

Partnership

NovaBay Pharmaceuticals and Eyenovia to Collaborate in Co-Promoting Prescription Ophthalmic Products in the US

Published Wed, Mar 13 2024 11:00 AM UTC

In a strategic move to expand their market presence and offer a comprehensive range of ophthalmic solutions, NovaBay Pharmaceuticals and Eyenovia have recently entered into a co-promotion agreement. This partnership aims to enable both companies to effectively reach eyecare professionals across the United States. By leveraging their respective channels and sales teams, NovaB...

Product Service News

Eyenovia Expands Manufacturing Capacity with Approval of Redwood City Facility

Published Tue, Feb 13 2024 12:00 PM UTC

Eyenovia, a leading pharmaceutical company specializing in eye care solutions, has recently announced the approval of Redwood City, California as its new commercial manufacturing facility. This comes as part of the company's expansion plans to meet the growing demand for its innovative product, Mydcombi. The facility in Redwood City will complement Eyenovia's existing manufa...

Eyenovia Inc

Eyenovia Inc Reveals Promising Q3 2023 Financial Report with Revenue of $1.2 Million



As the third quarter of the 2023 earnings season comes to a close, Eyenovia Inc ? a leading biopharmaceutical company specializing in innovative ophthalmology solutions ? has reported revenue of $0.001198 million. Although seemingly modest, this figure indicates some positive progress for the company. However, Eyenovia Inc also revealed a larger-than-expected net deficit of $-7.339 million, reflecting the hurdles faced during this period.
Comparing the net deficit of this quarter with the previous year, the company's financial results indicate a slight increase from $-7.309 million. This difference, while modest, suggests that Eyenovia Inc faced challenges that hindered its overall financial performance during the third quarter of 2023 earnings season.

Eyenovia Inc

Eyenovia Inc Reports Significant Growth in Jun 30, 2023 Financial Results Despite Operating Shortfall of $-5.96087 Million



Eyenovia Inc, a major player in the pharmaceutical preparations industry, recently reported its financial results for the period ending June 30, 2023. Despite a decline in stock value over the past week, the company's year-to-date performance has been strong. This article will analyze the impact of the financial results on Eyenovia Inc's future prospects.
Financial Results:
During the reporting period, Eyenovia Inc experienced an operating shortfall of $-5.96087 million, marking an improvement from the previous year. In the same period last year, the operating deficit stood at $-7.121456 million. Furthermore, the company managed to reduce its deficit from the second quarter of 2022, with a decline from $-7.239 million to $-6.216 million.






 

Eyenovia Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Eyenovia Inc does not provide revenue guidance.

Earnings Outlook
Eyenovia inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com